Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease (Q37004363)

17 August 2017

1 reference

title

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease (English)

1 reference

17 August 2017

0 references

1 reference

2

Krista L Lanctôt

1 reference

17 August 2017

Nathan Herrmann

1

1 reference

PubMed ID

18020111

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Canadian Journal of Psychiatry

17 August 2017

1 reference

17 August 2017

52

1 reference

17 August 2017

10

1 reference

17 August 2017

630-646

1 reference

The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland

17 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Survival of outpatients with Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Predictors of cognitive and functional progression in patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Dementia: the experience of family caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Predicting caregiver burden and depression in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Determinants of carer stress in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Role of serotonin in the behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The role of norepinephrine in the behavioral and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Resident characteristics associated with wandering in nursing homes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Medical correlates of agitation in nursing home residents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The relationship between vision impairment and the assessment of disruptive behaviors among nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Agitated behaviors in the elderly. I. A conceptual review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The Overt Aggression Scale for the objective rating of verbal and physical aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Aggressive behavior in hospitalized psychogeriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Nonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Recommendations for the management of behavioral and psychological symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Antipsychotic use in the elderly: shifting trends and increasing costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Do atypical antipsychotics cause stroke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Atypical antipsychotics and risk of cerebrovascular accidents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Valproate-associated dysmyelopoiesis in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Occurrence of thrombocytopenia in psychiatric patients taking valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Antiglutamatergic therapy in Alzheimer's disease--effects of lamotrigine. Short communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Treatment of psychotic symptoms with lamotrigine in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Comparison of Thioridazine and Diazepam in the Control of Nonpsychotic Symptoms Associated with Senility: Double-Blind Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepien

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

The contribution of neuropsychiatric symptoms to the cost of dementia care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370705201004

10.1177/070674370705201004

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18020111